Compared with unmodified MSCs, administration of BM-MSCs overexpressing FGF-2 was more effective at reducing lung injury, edema, neutrophil counts, MPO activity, and TNF-α levels in experimental LPS-induced ARDS (Zhao et al., 2015). The gene discussed is MPO; the disease is acute respiratory distress syndrome.